Seropositive myasthenia gravis: a nationwide epidemiologic study.
about
Epidemiology of thymoma and associated malignancies.Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review.Repeated acetylcholine receptor antibody-concentrations and association to clinical myasthenia gravis development.Clinical Features of Neuromuscular Disorders in Patients with N-Type Voltage-Gated Calcium Channel AntibodiesClinical aspects of myasthenia explained.Myasthenia gravis and risks for comorbidity.Myasthenia gravis: recent advances in immunopathology and therapy.CD19+ Tim-1+ B cells are decreased and negatively correlated with disease severity in Myasthenia Gravis patients.Epidemiology of myasthenia gravis in Northern Portugal: Frequency estimates and clinical epidemiological distribution of cases.TIPE2 Play a Negative Role in TLR4-Mediated Autoimmune T Helper 17 Cell Responses in Patients with Myasthenia Gravis.Myasthenia gravis requiring pyridostigmine treatment in a national population cohort.Myasthenia in pregnancy: best practice guidelines from a U.K. multispecialty working group.Smoking and socio-economic status may affect myasthenia gravis.Change in myasthenia gravis epidemiology in Trento, Italy, after twenty years.A national epidemiological study of Myasthenia Gravis in Australia.Geographical distribution of a seropositive myasthenia gravis population.Myasthenia gravis epidemiology in a national cohort; combining multiple disease registries.
P2860
Q34181900-037675BA-0A5E-4668-A853-7AADC926D700Q34212078-307269D8-F7FE-49CC-9D76-88C1F9B3531DQ34612356-E3B92B6C-44FD-4F70-A558-E17A9C4705F0Q37570823-C8C50EFF-F556-45CB-90D5-26CF2C8FF55EQ37727997-C31C229B-6A7B-4530-9787-3E83BE856F2FQ38263703-D94574B1-F627-467F-B93A-196013F7FC94Q38969032-B63D2322-E1CA-45E2-8899-EA1707B85348Q39345723-758C8DD2-AE8D-4F79-9E51-6600C827FF2CQ40017924-23F1270B-1193-468D-B62F-B4C725C08A87Q40394415-7E3EB7BE-7D97-4675-BE8E-289FEAEE9E22Q43057271-C56544B3-F94A-468A-9599-FCDD69FDF369Q44615844-55EA8DC4-3358-49EE-88CA-CAD0E6304266Q45096052-E0838A5E-668D-4BE5-BBE9-7BACC1DA307DQ51167258-A9F28AEF-3DDC-4995-BCDA-F77D19FA66D2Q51182046-C77C6536-FB44-452C-BFB2-0192A4C9539EQ51184467-1293BBFE-8365-41C4-8D69-32265E304281Q51240646-97D9B77C-360D-4DA1-8449-8CBEEECFB3A2
P2860
Seropositive myasthenia gravis: a nationwide epidemiologic study.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Seropositive myasthenia gravis: a nationwide epidemiologic study.
@en
Seropositive myasthenia gravis: a nationwide epidemiologic study.
@nl
type
label
Seropositive myasthenia gravis: a nationwide epidemiologic study.
@en
Seropositive myasthenia gravis: a nationwide epidemiologic study.
@nl
prefLabel
Seropositive myasthenia gravis: a nationwide epidemiologic study.
@en
Seropositive myasthenia gravis: a nationwide epidemiologic study.
@nl
P2093
P1433
P1476
Seropositive myasthenia gravis: a nationwide epidemiologic study.
@en
P2093
Anne Taraldsen Heldal
Fredrik Romi
Jone Furlund Owe
P304
P356
10.1212/WNL.0B013E3181AD53C2
P407
P577
2009-07-01T00:00:00Z